LIVE

RLAY

Relay Therapeutics, Inc.

RLAY

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.1B

$18.65

▲ +5.01%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$3.03 - $19.93

P/E

-11.88

Fwd P/E

-11.15

Beta

1.75

Div Yield

0.00%

Avg Vol

4.3M

Shares Out

178.7M

Mkt Cap

$3.1B

Price action

Price chart

Up 393.3% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary protein dynamics and motion analysis technology platform
  • Strategic partnership with D. E. Shaw Research for computational drug discovery
  • Collaboration with Genentech providing development expertise and commercialization reach
  • Focus on previously undruggable targets through innovative structural biology approach
▼

Bear Case

1 risk

  • Above-average volatility (beta 1.7).

Growth

Stable outlook

Clinical trial progression of RLY-4008, RLY-2608, and RLY-1971 through development stages

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+41.6% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

MAY 5, 2026

Reported EPS of -$0.41 vs -$0.35 consensus (-17.1% surprise). Revenue of $3.0M vs $5.6M expected (-46.2%).

EPS miss
Revenue miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-17.1%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

—

-23%

—

—

—

-61%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$7.7M

$677.0K

$0

$7.0M

$3.0M

Margins · last 8Q

Gross

—

Profit

-2443.0%

View full earnings history →

Wall Street consensus

8 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

8

100%

Hold

0%

Sell

0%

Median Price Target

$25.50

▲ +36.7% vs $18.65

Low $18.00
Median $25.50
High $28.00

Latest: HC Wainwright · $28.00 · May 26, 2026

7 analysts covering

View full analyst page →

vs Industry

How RLAY stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.